Hjalmar Flygt

Hjalmar Flygt (MD, PhD candidate) is a senior resident physician specializing in internal medicine. He has a broad interest and experience in the field of internal medicine, with a clinical focus on emergency medicine, thromboembolic and cardiovascular diseases.

As a doctoral student at Uppsala University, Hjalmar conducts research in the field of hematology with a focus on chronic myeloid leukemia, including clinical phase II trials as well as genetic and registry-based studies. Hjalmar has been a CTC associate since 2019 and has served as a co-investigator in 20+ early phase clinical trials. 

• Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study
  januari 11, 2022
• Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study
  augusti 21, 2021
• Successful tyrosine kinase inhibitor discontinuation outside clinical trials – data from the population-based Swedish chronic myeloid leukaemia registry
  mars 30, 2021
• Neurosurgical untethering with or without syrinx drainage results in high patient satisfaction and favorable clinical outcome in post-traumatic myelopathy patients
  mars 29, 2018